Hannan Enda, Roman Lorena Martin, O'Brien Lukas, Mueller Anna, Staunton Oonagh, Shields Conor, Aird John, Mulsow Jurgen
The National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital, Dublin, Ireland.
Department of Histopathology and Cytopathology, Mater Misericordiae University Hospital, Dublin, Ireland.
Colorectal Dis. 2024 Dec 17;27(1). doi: 10.1111/codi.17266.
Low-grade appendiceal mucinous neoplasm (LAMN) of the appendix is a rare tumour that can progress to pseudomyxoma peritonei (PMP). There is a lack of standardization of surveillance following resection of LAMN as the progression rate to PMP is unclear. The aim of this study was to evaluate the rate of progression following resection of LAMN to PMP in a structured surveillance programme.
Data for all patients referred for LAMN surveillance from 2013 to 2021 were retrospectively collected. The surveillance regime consisted of annual CT and tumour markers for a 5-year period. Patients who progressed to PMP were identified.
Of the patients enrolled in surveillance following appendicectomy and LAMN diagnosis (65.1% female, median age 56 years), 83 had completed at least 1 year of surveillance (median follow-up 24 months). Of these, 6% (n = 5) showed disease progression during follow-up. The median time to progression was 23 months. Survival analysis revealed no statistically significant difference in progression with regards to T staging (p = 0.39), margin positivity (p = 0.11) or appendiceal perforation (p = 0.26). No patients with Tis disease developed PMP. A statistically significant difference in progression was seen in patients with M1b staging (p = 0.021) and in those with mucin beyond the right iliac fossa at diagnosis (p = 0.04).
The observed progression rate justifies the necessity of postappendicectomy surveillance in patients with LAMN, with the risk of progression being highest within the first 3 years of diagnosis. The described surveillance programme allows for early detection of subclinical progression to PMP.
阑尾低级别黏液性肿瘤(LAMN)是一种罕见肿瘤,可进展为腹膜假黏液瘤(PMP)。由于LAMN切除术后进展为PMP的发生率尚不清楚,因此缺乏LAMN切除术后监测的标准化方案。本研究的目的是评估在结构化监测方案中LAMN切除术后进展为PMP的发生率。
回顾性收集2013年至2021年所有因LAMN监测而转诊患者的数据。监测方案包括为期5年的每年一次CT检查和肿瘤标志物检测。确定进展为PMP的患者。
在阑尾切除术后诊断为LAMN并纳入监测的患者中(65.1%为女性,中位年龄56岁),83例完成了至少1年的监测(中位随访24个月)。其中,6%(n = 5)在随访期间出现疾病进展。进展的中位时间为23个月。生存分析显示,在T分期(p = 0.39)、切缘阳性(p = 0.11)或阑尾穿孔(p = 0.26)方面,进展无统计学显著差异。Tis期疾病患者均未发生PMP。M1b分期患者(p = 0.021)和诊断时黏液超出右髂窝的患者(p = 0.04)在进展方面存在统计学显著差异。
观察到的进展率证明了LAMN患者阑尾切除术后监测的必要性,诊断后的前3年内进展风险最高。所描述的监测方案能够早期检测到向PMP的亚临床进展。